Jazz Pharma Ireland Ltd v. Tris Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Jazz Pharmaceuticals Ireland Limited (Ireland)
  • Defendant: Tris Pharma, Inc. (New Jersey)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-01740, D.N.J., 02/20/2026
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey because the Defendant, Tris Pharma, Inc., is a New Jersey corporation with its principal place of business in the district, and because the district is a likely destination for the accused product.
• Core Dispute: Plaintiff alleges that Defendant's submission of a New Drug Application to the FDA for a generic version of Plaintiff's Xywav® drug product constitutes an act of patent infringement under the Hatch-Waxman Act.
• Technical Context: The technology concerns pharmaceutical compositions of gamma-hydroxybutyrate (GHB), a central nervous system depressant used to treat sleep disorders such as narcolepsy.
• Key Procedural History: The lawsuit was triggered by Defendant's submission of New Drug Application (NDA) No. 220138 with a Paragraph IV Certification. This certification alleges that Plaintiff's patents listed in the FDA's Orange Book for the drug Xywav® are invalid, unenforceable, or will not be infringed by Defendant's proposed generic product. This act serves as the statutory basis for the infringement suit.

Case Timeline

Date	Event
2012-12-14	Earliest Priority Date for '922, '306, '173, '302, '107, '168, '258 Patents
2013-11-26	U.S. Patent No. 8,591,922 Issued
2014-07-08	U.S. Patent No. 8,772,306 Issued
2014-12-02	U.S. Patent No. 8,901,173 Issued
2015-06-09	U.S. Patent No. 9,050,302 Issued
2015-09-15	U.S. Patent No. 9,132,107 Issued
2016-11-08	U.S. Patent No. 9,486,426 Issued
2019-02-05	U.S. Patent No. 10,195,168 Issued
2019-02-26	U.S. Patent No. 10,213,400 Issued
2020-06-09	U.S. Patent No. 10,675,258 Issued
2020-12-15	U.S. Patent No. 10,864,181 Issued
2022-02-22	U.S. Patent No. 11,253,494 Issued
2022-08-30	U.S. Patent No. 11,426,373 Issued
2023-01-17	U.S. Patent No. 11,554,102 Issued
2024-05-21	U.S. Patent No. 11,986,446 Issued
2024-11-12	U.S. Patent No. 12,138,233 Issued
2026-01-09	Earliest date Defendant sent Paragraph IV Notice Letter
2026-02-20	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,591,922 - "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders"

• Patent Identification: U.S. Patent No. 8,591,922, issued November 26, 2013.

The Invention Explained

• Problem Addressed: The patent addresses the problem that existing gamma-hydroxybutyrate (GHB) formulations, such as sodium oxybate (NaGHB), require high doses that contribute a significant and undesirable amount of sodium to a patient's diet, posing risks for those with conditions like hypertension or heart disease '168 Patent, col. 1:56-col. 2:6
• The Patented Solution: The invention provides pharmaceutical compositions comprising a mixture of different GHB salts, such as sodium, potassium, magnesium, and calcium salts '168 Patent, abstract This "mixed salt" formulation is designed to deliver a therapeutically effective dose of GHB while reducing the total sodium load compared to a formulation consisting solely of NaGHB '168 Patent, col. 2:34-40
• Technical Importance: This approach allows for chronic GHB therapy in a broader patient population, including those for whom high sodium intake is a medical concern.

Key Claims at a Glance

• The complaint asserts infringement of one or more unspecified claims of the '922 patent Compl. ¶ 37 Independent claim 1 is representative of the patent's composition claims.
• Independent Claim 1: A pharmaceutical composition comprising:
  • a mixture of salts of gamma-hydroxybutyrate (GHB)
  • wherein the mixture comprises a sodium salt of GHB, a potassium salt of GHB, a magnesium salt of GHB, and a calcium salt of GHB
  • wherein the salts are present in a wt/wt % ratio of about 8%:32%:20%:40%, respectively.
• The complaint does not explicitly reserve the right to assert dependent claims but makes broad allegations covering "one or more claims" Compl. ¶ 37

U.S. Patent No. 8,772,306 - "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters"

• Patent Identification: U.S. Patent No. 8,772,306, issued July 8, 2014.

The Invention Explained

• Problem Addressed: The patent addresses the drug-drug interaction that occurs when GHB is administered concomitantly with inhibitors of monocarboxylate transporters (MCTs), which can alter the therapeutic effect and safety profile of GHB '400 Patent, col. 1:4-14
• The Patented Solution: The invention provides a method for safely administering GHB to a patient who is also taking an MCT inhibitor (such as valproate). The method involves administering a reduced dosage amount of GHB to compensate for the potentiating effect of the MCT inhibitor, thereby diminishing potentially unsafe additive effects '400 Patent, col. 1:15-24
• Technical Importance: This method provides a protocol for managing a known drug-drug interaction, enhancing the safety of concurrent GHB and MCT inhibitor therapy for patients with comorbidities.

Key Claims at a Glance

• The complaint asserts infringement of one or more unspecified claims of the '306 patent Compl. ¶ 46 Independent claim 1 is representative of the patent's method claims.
• Independent Claim 1: A method for reducing adverse effects caused by a combination of GHB and divalproex sodium in a patient, comprising:
  • administering a reduced daily dosage amount of GHB or a salt thereof to the patient of between about 5% to about 35%
  • compared to a daily dosage amount of GHB or salt thereof administered to the patient in the absence of concomitant administration of divalproex sodium
  • wherein the patient is concomitantly administered divalproex sodium.
• The complaint does not explicitly reserve the right to assert dependent claims but makes broad allegations covering "one or more claims" Compl. ¶ 46

For brevity, the remaining 13 patents-in-suit are summarized below.

Multi-Patent Capsule: U.S. Patent No. 8,901,173

• Patent Identification: '173 patent, "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders," issued December 2, 2014 Compl. ¶ 6
• Technology Synopsis: Similar to the '922 patent, this patent relates to mixed-salt GHB compositions designed to reduce sodium content while treating disorders like narcolepsy Compl. ¶ 6
• Asserted Claims: One or more unspecified claims Compl. ¶ 55
• Accused Features: Tris's proposed oxybate product, which is alleged to be a mixed-salt formulation, is accused of infringement Compl. ¶ 32 Compl. ¶ 55

Multi-Patent Capsule: U.S. Patent No. 9,050,302

• Patent Identification: '302 patent, "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued June 9, 2015 Compl. ¶ 7
• Technology Synopsis: Similar to the '306 patent, this patent covers methods of safely co-administering GHB with MCT inhibitors by adjusting the GHB dosage Compl. ¶ 7
• Asserted Claims: One or more unspecified claims Compl. ¶ 64
• Accused Features: The act of submitting an NDA with a proposed label that allegedly instructs or encourages the claimed method of administration Compl. ¶ 23 Compl. ¶ 64

The complaint asserts twelve additional patents which are substantially similar in technology to those analyzed above, covering either mixed-salt GHB compositions or methods of administering GHB with MCT inhibitors Compl. ¶¶8-18 Compl. ¶¶72-170

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is "Tris's Proposed Product," an oxybate product for which Tris Pharma, Inc. submitted New Drug Application (NDA) No. 220138 for FDA approval Compl. ¶ 1 Compl. ¶ 32

Functionality and Market Context

• The complaint alleges that Tris's Proposed Product is a generic version of Jazz's Xywav® drug, which is a formulation of calcium, magnesium, potassium, and sodium oxybates Compl. ¶ 1 Compl. ¶ 19 The infringement claim is not based on an existing product but is a statutory act of infringement under 35 U.S.C. § 271(e)(2)(A), arising from the submission of the NDA seeking approval to market a drug product claimed in a patent before its expiration Compl. ¶ 37 The product is intended for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy, and for the treatment of idiopathic hypersomnia Compl. ¶ 21

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

The complaint does not contain element-by-element infringement allegations. The following charts summarize the infringement theory based on the general allegations in the complaint.

'922 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A pharmaceutical composition comprising a mixture of salts of gamma-hydroxybutyrate (GHB),	Tris's Proposed Product is alleged to be an oxybate product, which is a salt of GHB, and is alleged to contain a mixture of salts.	¶32	col. 2:34-40
wherein the mixture comprises a sodium salt of GHB, a potassium salt of GHB, a magnesium salt of GHB, and a calcium salt of GHB,	Tris's Proposed Product is alleged to be a generic version of Xywav®, which contains calcium, magnesium, potassium, and sodium oxybates.	¶19	col. 2:40-45
wherein the salts are present in a wt/wt % ratio of about 8%:32%:20%:40%, respectively.	Tris's Proposed Product, as described in its confidential NDA, is alleged to contain salts in proportions that infringe the claimed ratio.	¶37	col. 10:48-52

• Identified Points of Contention:
  • Scope Questions: A central question for the court will be whether the specific formulation of "Tris's Proposed Product," as detailed in its confidential NDA, falls within the scope of the claimed wt/wt % ratios. The complaint does not provide these formulation details.
  • Technical Questions: The analysis will depend on the chemical analysis of Tris's product to determine if it is, in fact, a mixture of the four specified salts and if their relative proportions meet the "about 8%:32%:20%:40%" limitation.

'306 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for reducing adverse effects...comprising: administering a reduced daily dosage amount of GHB or a salt thereof to the patient of between about 5% to about 35%, compared to a daily dosage amount...in the absence of concomitant administration of divalproex sodium;	The labeling for Xywav®, which Tris's proposed label is expected to mimic, is alleged to instruct physicians to modify the dose of Xywav® for patients also receiving divalproex sodium (valproate).	¶22	col. 1:33-44
wherein the patient is concomitantly administered divalproex sodium.	The complaint alleges that the proposed labeling for Tris's product will instruct and encourage the concomitant administration of the oxybate product with divalproex sodium for certain patients.	¶22	col. 1:4-14

• Identified Points of Contention:
  • Scope Questions: A key issue will be one of label interpretation. Does the alleged instruction to "modify the dose" Compl. ¶ 22 on the proposed generic label meet the claim limitation of "administering a reduced daily dosage amount...of between about 5% to about 35%"? This raises the question of whether a general instruction to modify a dose induces infringement of a claim requiring a specific quantitative reduction.
  • Technical Questions: Evidence of infringement will depend entirely on the content of the proposed label submitted with Tris's NDA. The complaint alleges the Xywav® label contains such instructions, suggesting the generic label will as well Compl. ¶ 22

V. Key Claim Terms for Construction

• The Term: "a mixture of salts" (from '922 patent, claim 1)

• Context and Importance: The definition of this term is critical because infringement of the composition patents hinges on whether Tris's product contains a specific combination of GHB salts that qualifies as the claimed "mixture." Practitioners may focus on whether this term requires the presence of all four specified cations (Na, K, Mg, Ca) or if a combination of a subset could still be considered a "mixture."

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification describes compositions comprising "two or more salts" (e.g.,'168 Patent, col. 2:40-42), which may support an interpretation that a mixture does not require all four cations.
  • Evidence for a Narrower Interpretation: Claim 1 of the '922 patent explicitly recites a mixture comprising all four specified salts. Specific embodiments and examples in the patent detailing four-salt mixtures could be used to argue that "a mixture" in the context of this claim requires all four components '168 Patent, Table 3, Mixture A

• The Term: "administering a reduced daily dosage amount" (from '306 patent, claim 1)

• Context and Importance: This term is central to the method patent dispute. Infringement requires not just a dose adjustment, but a specific "reduced" amount. The case may turn on whether the alleged instruction on the proposed label to "modify the dose" Compl. ¶ 22 necessarily directs a reduction, as required by the claim.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The patent's summary describes the invention as providing an "adjusted dosage amount" when co-administered with an MCT inhibitor, which could be argued to encompass any modification '400 Patent, col. 1:32-34
  • Evidence for a Narrower Interpretation: The detailed description repeatedly frames the adjustment as a "reduced amount" to "diminish the additive effects" of the drug combination, suggesting the term requires a downward, not merely modified, dose adjustment '400 Patent, col. 2:11-15

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for all asserted patents Compl. ¶¶40-41 Compl. ¶¶49-50 For method claims, inducement is based on the allegation that the label for Tris's Proposed Product will instruct and encourage physicians and patients to perform the claimed methods of administration, such as modifying the dose when co-administered with valproate Compl. ¶ 22 Compl. ¶ 23
• Willful Infringement: The complaint does not use the term "willful" but alleges the case is "exceptional" and seeks attorneys' fees under 35 U.S.C. § 285 Compl. ¶ 44 This allegation is based on Tris's alleged knowledge of the patents-in-suit via their listing in the FDA's Orange Book and its decision to file an NDA with a Paragraph IV certification despite this knowledge Compl. ¶ 20 Compl. ¶ 34

VII. Analyst's Conclusion: Key Questions for the Case

• A primary issue will be one of formulation equivalence: does the specific chemical composition of Tris's Proposed Product, as confidentially described in its NDA, fall within the scope of the weight-percent ratios of the various cations claimed in Jazz's composition patents? This is a factual question that will depend on discovery into the contents of NDA No. 220138.
• A second core issue will be one of induced infringement from the proposed label: will the instructions on the label of Tris's Proposed Product be found to actively encourage or instruct medical professionals to perform the specific, quantitatively defined dosage adjustments required by Jazz's method patents when the drug is co-administered with MCT inhibitors?